WO2001047498A3 - Hydrogel-driven layered drug dosage form comprising sertraline - Google Patents
Hydrogel-driven layered drug dosage form comprising sertraline Download PDFInfo
- Publication number
- WO2001047498A3 WO2001047498A3 PCT/IB2000/001871 IB0001871W WO0147498A3 WO 2001047498 A3 WO2001047498 A3 WO 2001047498A3 IB 0001871 W IB0001871 W IB 0001871W WO 0147498 A3 WO0147498 A3 WO 0147498A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sertraline
- dosage form
- hour
- water
- use environment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXPA02006335A MXPA02006335A (en) | 1999-12-23 | 2000-12-13 | Hydrogeldriven layered drug dosage form. |
AU17243/01A AU1724301A (en) | 1999-12-23 | 2000-12-13 | Hydrogel-driven layered drug dosage form |
CA002395231A CA2395231C (en) | 1999-12-23 | 2000-12-13 | Hydrogel-driven layered drug dosage form |
JP2001548093A JP2003518487A (en) | 1999-12-23 | 2000-12-13 | Hydrogel-driven laminated drug formulation |
EP00979866A EP1239839A2 (en) | 1999-12-23 | 2000-12-13 | Hydrogel-driven layered drug dosage form comprising sertraline |
BR0016707-0A BR0016707A (en) | 1999-12-23 | 2000-12-13 | Hydrogel-driven layered drug dosage form |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17210899P | 1999-12-23 | 1999-12-23 | |
US60/172,108 | 1999-12-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001047498A2 WO2001047498A2 (en) | 2001-07-05 |
WO2001047498A3 true WO2001047498A3 (en) | 2001-11-15 |
Family
ID=22626396
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2000/001871 WO2001047498A2 (en) | 1999-12-23 | 2000-12-13 | Hydrogel-driven layered drug dosage form comprising sertraline |
Country Status (15)
Country | Link |
---|---|
US (1) | US6899896B2 (en) |
EP (1) | EP1239839A2 (en) |
JP (1) | JP2003518487A (en) |
AR (1) | AR027066A1 (en) |
AU (1) | AU1724301A (en) |
BR (1) | BR0016707A (en) |
CA (1) | CA2395231C (en) |
CO (1) | CO5271728A1 (en) |
GT (1) | GT200000220A (en) |
MX (1) | MXPA02006335A (en) |
PA (1) | PA8508901A1 (en) |
PE (1) | PE20010983A1 (en) |
TN (1) | TNSN00251A1 (en) |
UY (1) | UY26493A1 (en) |
WO (1) | WO2001047498A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9060941B2 (en) | 2002-09-20 | 2015-06-23 | Actavis, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100523127B1 (en) * | 1999-12-23 | 2005-10-20 | 화이자 프로덕츠 인코포레이티드 | Hydrogel-driven drug dosage form |
BR0211028A (en) * | 2001-06-22 | 2004-06-15 | Pfizer Prod Inc | Aqueous solution, method for forming drug and polymer combinations, pharmaceutical compositions, method for forming a pharmaceutical composition and product |
JP2004534812A (en) | 2001-06-22 | 2004-11-18 | ファイザー・プロダクツ・インク | Pharmaceutical composition of dispersion of drug and neutral polymer |
MXPA04002979A (en) * | 2001-09-28 | 2005-06-20 | Johnson & Johnson | Modified release dosage forms. |
US20040146559A1 (en) * | 2002-09-28 | 2004-07-29 | Sowden Harry S. | Dosage forms having an inner core and outer shell with different shapes |
EP1469832B2 (en) | 2002-02-01 | 2016-10-26 | Bend Research, Inc. | Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials |
GB0203296D0 (en) | 2002-02-12 | 2002-03-27 | Glaxo Group Ltd | Novel composition |
US8637512B2 (en) | 2002-07-29 | 2014-01-28 | Glaxo Group Limited | Formulations and method of treatment |
ES2529180T3 (en) * | 2002-09-20 | 2015-02-17 | Andrx Labs Llc | Multi-stage formulation containing a biguanide and a thiazolidinedione derivative |
US7959946B2 (en) | 2002-09-20 | 2011-06-14 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US8084058B2 (en) | 2002-09-20 | 2011-12-27 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US7785627B2 (en) | 2002-09-20 | 2010-08-31 | Watson Pharmaceuticals, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
US20040081695A1 (en) * | 2002-09-28 | 2004-04-29 | Sowden Harry S | Dosage forms having an inner core and an outer shell |
RU2310647C2 (en) * | 2002-11-07 | 2007-11-20 | Торрент Фармасьютикалз Лтд | Method for preparing sertraline hydrochloride polymorphous formulation |
CA2415154C (en) * | 2002-12-24 | 2009-06-16 | Biovail Laboratories Inc. | Modified release formulations of selective serotonin re-uptake inhibitors |
ATE540671T1 (en) | 2003-08-04 | 2012-01-15 | Bend Res Inc | PHARMACEUTICAL COMPOSITIONS OF AMORPHOUS DRUG ADSORBATES AND LIPOPHILIC MICROPHASE-FORMING MATERIALS |
WO2005117911A2 (en) * | 2004-05-06 | 2005-12-15 | Cydex, Inc. | Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin |
WO2006072878A1 (en) * | 2005-01-07 | 2006-07-13 | Ranbaxy Laboratories Limited | Oral dosage forms of sertraline having controlled particle size and processes for their preparation |
US20060233882A1 (en) * | 2005-04-15 | 2006-10-19 | Sowden Harry S | Osmotic dosage form |
US20060239956A1 (en) * | 2005-04-26 | 2006-10-26 | Lulu Henson | Preparation and use of hydrogels |
CN101299993A (en) * | 2005-11-04 | 2008-11-05 | 伊士曼化工公司 | Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents |
WO2007057762A2 (en) * | 2005-11-16 | 2007-05-24 | Pfizer Limited | Osmotic bi-layer tablet |
CN100563637C (en) * | 2006-10-13 | 2009-12-02 | 北京红林制药有限公司 | A kind of medicated core compositions of controlled release drug administration and controlled release preparation and preparation method thereof |
ECSP077628A (en) * | 2007-05-03 | 2008-12-30 | Smithkline Beechman Corp | NEW PHARMACEUTICAL COMPOSITION |
AU2010325894B2 (en) * | 2009-12-04 | 2015-07-30 | Sunovion Pharmaceuticals Inc. | Formulations, salts and polymorphs of transnorsertraline and uses thereof |
US10485770B2 (en) | 2009-12-21 | 2019-11-26 | Aptapharma, Inc. | Functionally-coated multilayer tablets |
WO2016020936A2 (en) * | 2014-07-21 | 2016-02-11 | Patel Jayendrakumar Dasharathlal | A novel oral gastroretentive pharmaceutical dosage form |
JP6455293B2 (en) * | 2015-04-21 | 2019-01-23 | ニプロ株式会社 | Formulation containing sertraline and / or a pharmaceutically acceptable salt thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997037640A2 (en) * | 1996-04-05 | 1997-10-16 | Alza Corporation | Uniform drug delivery therapy |
WO1999001121A1 (en) * | 1997-07-01 | 1999-01-14 | Pfizer Inc. | Sertraline salts and sustained-release dosage forms of sertraline |
EP1027888A2 (en) * | 1999-02-10 | 2000-08-16 | Pfizer Products Inc. | Osmotic system for delivery of solid amorphous dispersions of drugs |
Family Cites Families (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4536518A (en) | 1979-11-01 | 1985-08-20 | Pfizer Inc. | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine |
US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
US5366738A (en) | 1982-07-29 | 1994-11-22 | Merck & Co., Inc. | Controlled release drug dispersion delivery device |
US4612008A (en) | 1983-05-11 | 1986-09-16 | Alza Corporation | Osmotic device with dual thermodynamic activity |
US4783337A (en) | 1983-05-11 | 1988-11-08 | Alza Corporation | Osmotic system comprising plurality of members for dispensing drug |
US5082668A (en) | 1983-05-11 | 1992-01-21 | Alza Corporation | Controlled-release system with constant pushing source |
US4765989A (en) | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
USRE33994E (en) | 1983-08-16 | 1992-07-14 | Burroughs Wellcome Co. | Pharmaceutical delivery system |
US4968507A (en) | 1984-06-20 | 1990-11-06 | Merck & Co., Inc. | Controlled porosity osmotic pump |
US4609374A (en) | 1985-04-22 | 1986-09-02 | Alza Corporation | Osmotic device comprising means for governing initial time of agent release therefrom |
US4624847A (en) | 1985-04-22 | 1986-11-25 | Alza Corporation | Drug delivery device for programmed delivery of beneficial drug |
GB8518301D0 (en) | 1985-07-19 | 1985-08-29 | Fujisawa Pharmaceutical Co | Hydrodynamically explosive systems |
US4865598A (en) | 1985-08-16 | 1989-09-12 | Alza Corporation | Dispensing system for administering beneficial agent |
GB8521494D0 (en) | 1985-08-29 | 1985-10-02 | Zyma Sa | Controlled release tablet |
IT1188212B (en) | 1985-12-20 | 1988-01-07 | Paolo Colombo | SYSTEM FOR THE RELEASE SPEED OF ACTIVE SUBSTANCES |
US4755180A (en) | 1986-06-16 | 1988-07-05 | Alza Corporation | Dosage form comprising solubility regulating member |
DE3868077D1 (en) | 1987-01-14 | 1992-03-12 | Ciba Geigy Ag | THERAPEUTIC SYSTEM FOR HEAVY-SOLUBLE ACTIVE SUBSTANCES. |
US4915954A (en) | 1987-09-03 | 1990-04-10 | Alza Corporation | Dosage form for delivering a drug at two different rates |
US4946687A (en) | 1987-10-02 | 1990-08-07 | Alza Corporation | Dosage form for treating cardiovascular diseases |
US4971998A (en) | 1987-10-22 | 1990-11-20 | Massachusetts Institute Of Technology | Methods for treating the premenstrual or late luteal phase syndrome |
US4837111A (en) | 1988-03-21 | 1989-06-06 | Alza Corporation | Dosage form for dispensing drug for human therapy |
FI101344B1 (en) | 1988-03-31 | 1998-06-15 | Tanabe Seiyaku Co | Process for the preparation of a composition for controlled release of a pharmaceutically active substance |
US5030456A (en) | 1988-11-07 | 1991-07-09 | Alza Corporation | Dosage form for treating cardiovascular diseases |
US5034229A (en) | 1988-12-13 | 1991-07-23 | Alza Corporation | Dispenser for increasing feed conversion of hog |
IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Dispensing devices powered by hydrogel |
DD295760A5 (en) | 1989-01-31 | 1991-11-14 | Martin-Luther-Universitaet Halle Wittenberg,De | DRUG DISTRIBUTION SYSTEM WITH COTROLLED ACTIVE INGREDIENT TRANSFER |
US4981870A (en) | 1989-03-07 | 1991-01-01 | Pfizer Inc. | Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants |
US5019396A (en) | 1989-05-12 | 1991-05-28 | Alza Corporation | Delivery dispenser for treating cardiac arrhythmias |
US5126142A (en) | 1989-07-18 | 1992-06-30 | Alza Corporation | Dispenser comprising ionophore |
US5273752A (en) | 1989-07-18 | 1993-12-28 | Alza Corporation | Controlled release dispenser comprising beneficial agent |
US4940731A (en) | 1989-08-30 | 1990-07-10 | Pfizer Inc. | Method of treating premature ejaculation using sertraline |
US5130338A (en) | 1989-08-30 | 1992-07-14 | Pfizer Inc. | Method of treating chemical dependencies using sertraline |
US5091190A (en) | 1989-09-05 | 1992-02-25 | Alza Corporation | Delivery system for administration blood-glucose lowering drug |
US5035897A (en) | 1989-09-05 | 1991-07-30 | Alza Corporation | Dosage form for delivering soluble or insoluble drugs |
US4962128A (en) | 1989-11-02 | 1990-10-09 | Pfizer Inc. | Method of treating anxiety-related disorders using sertraline |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5200197A (en) | 1989-11-16 | 1993-04-06 | Alza Corporation | Contraceptive pill |
US5178866A (en) | 1990-03-23 | 1993-01-12 | Alza Corporation | Dosage form for delivering drug to the intestine |
US5190763A (en) | 1990-05-07 | 1993-03-02 | Alza Corporation | Dosage form indicated for the management of abnormal posture, tremor and involuntary movement |
US5221536A (en) | 1990-05-07 | 1993-06-22 | Alza Corporation | Dosage form indicated for the management of abnormal posture, tremor and involuntary movement |
US5192550A (en) | 1990-05-07 | 1993-03-09 | Alza Corporation | Dosage form for treating central nervous system disorders |
US5057321A (en) | 1990-06-13 | 1991-10-15 | Alza Corporation | Dosage form comprising drug and maltodextrin |
US5128145A (en) | 1990-06-13 | 1992-07-07 | Alza Corporation | Dosage form for Parkinson's disease, spasticity and muscle spasms |
US5156850A (en) | 1990-08-31 | 1992-10-20 | Alza Corporation | Dosage form for time-varying patterns of drug delivery |
DE69102140T2 (en) | 1990-09-28 | 1994-09-08 | Pfizer | ACTIVE SUBSTANCE DELIVERY DEVICE CONTAINING A HYDROPHOBIC AGENT. |
US5284662A (en) | 1990-10-01 | 1994-02-08 | Ciba-Geigy Corp. | Oral osmotic system for slightly soluble active agents |
US5208037A (en) | 1991-04-22 | 1993-05-04 | Alza Corporation | Dosage forms comprising polymers comprising different molecular weights |
US5160744A (en) | 1991-06-27 | 1992-11-03 | Alza Corporation | Verapmil therapy |
US5178867A (en) | 1991-08-19 | 1993-01-12 | Alza Corporation | Dosage form for delivering drug in short-time period |
CA2115648C (en) | 1991-10-10 | 2002-04-09 | Eun Soo Lee | Osmotic drug delivery devices with hydrophobic wall materials |
US5183942A (en) | 1991-11-05 | 1993-02-02 | The Scripps Research Institute | Ten-membered ring enediynediols and enediynediones having DNA cleaving properties |
US5543154A (en) | 1991-12-27 | 1996-08-06 | Merck & Co., Inc. | Controlled release nifedipine delivery device |
US5294770A (en) | 1992-01-14 | 1994-03-15 | Alza Corporation | Laser tablet treatment system with dual access to tablet |
US5246711A (en) | 1992-02-27 | 1993-09-21 | Alza Corporation | Dosage form for treating dysthymia |
US5185158A (en) | 1992-02-27 | 1993-02-09 | Alza Corporation | Dosage form comprising succinimide drug for treating depressive disorders and composition comprising same |
US5688518A (en) | 1992-02-27 | 1997-11-18 | Alza Corporation | Antidepressive therapy |
US5246710A (en) | 1992-02-27 | 1993-09-21 | Alza Corporation | Dosage form for treating cyclothymia |
US5609885A (en) | 1992-09-15 | 1997-03-11 | Alza Corporation | Osmotic membrane and delivery device |
US5260069A (en) | 1992-11-27 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Pulsatile particles drug delivery system |
US5358721A (en) | 1992-12-04 | 1994-10-25 | Alza Corporation | Antiviral therapy |
ATE195252T1 (en) | 1993-04-23 | 2000-08-15 | Novartis Erfind Verwalt Gmbh | DRUG DELIVERY DEVICE WITH CONTROLLED RELEASE |
US6287598B1 (en) | 1993-05-28 | 2001-09-11 | Alza Corporation | Method for providing sustained antiepileptic therapy |
US5455046A (en) | 1993-09-09 | 1995-10-03 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
HU213407B (en) | 1993-12-09 | 1997-06-30 | Egyt Gyogyszervegyeszeti Gyar | Process for producing tablet with diffusive-osmotic release |
US5458887A (en) | 1994-03-02 | 1995-10-17 | Andrx Pharmaceuticals, Inc. | Controlled release tablet formulation |
US5458888A (en) | 1994-03-02 | 1995-10-17 | Andrx Pharmaceuticals, Inc. | Controlled release tablet formulation |
ZA953078B (en) | 1994-04-28 | 1996-01-05 | Alza Corp | Effective therapy for epilepsies |
AU680356B2 (en) | 1994-05-06 | 1997-07-24 | Pfizer Inc. | Controlled-release dosage forms of azithromycin |
US5698224A (en) | 1994-06-27 | 1997-12-16 | Alza Corporation | Tacrine therapy |
US5529787A (en) | 1994-07-07 | 1996-06-25 | Alza Corporation | Hydromorphone therapy |
US5718700A (en) | 1994-09-20 | 1998-02-17 | Alza Corporation | Exit means in dosage form |
US5658474A (en) | 1994-12-16 | 1997-08-19 | Alza Corporation | Method and apparatus for forming dispenser delivery ports |
US5607696A (en) | 1995-02-10 | 1997-03-04 | Alza Corporation | Osmotic membrane and delivery device |
US5736159A (en) | 1995-04-28 | 1998-04-07 | Andrx Pharmaceuticals, Inc. | Controlled release formulation for water insoluble drugs in which a passageway is formed in situ |
US5654005A (en) | 1995-06-07 | 1997-08-05 | Andrx Pharmaceuticals, Inc. | Controlled release formulation having a preformed passageway |
US5840332A (en) | 1996-01-18 | 1998-11-24 | Perio Products Ltd. | Gastrointestinal drug delivery system |
US5837379A (en) | 1997-01-31 | 1998-11-17 | Andrx Pharmaceuticals, Inc. | Once daily pharmaceutical tablet having a unitary core |
AU7706598A (en) | 1997-05-30 | 1998-12-30 | Laboratorios Phoenix U.S.A., Inc. | Multi-layered osmotic device |
-
2000
- 2000-12-13 JP JP2001548093A patent/JP2003518487A/en not_active Withdrawn
- 2000-12-13 EP EP00979866A patent/EP1239839A2/en not_active Withdrawn
- 2000-12-13 BR BR0016707-0A patent/BR0016707A/en not_active IP Right Cessation
- 2000-12-13 CA CA002395231A patent/CA2395231C/en not_active Expired - Fee Related
- 2000-12-13 MX MXPA02006335A patent/MXPA02006335A/en active IP Right Grant
- 2000-12-13 WO PCT/IB2000/001871 patent/WO2001047498A2/en not_active Application Discontinuation
- 2000-12-13 AU AU17243/01A patent/AU1724301A/en not_active Abandoned
- 2000-12-20 UY UY26493A patent/UY26493A1/en not_active Application Discontinuation
- 2000-12-20 US US09/745,096 patent/US6899896B2/en not_active Expired - Fee Related
- 2000-12-21 PE PE2000001381A patent/PE20010983A1/en not_active Application Discontinuation
- 2000-12-21 CO CO00097187A patent/CO5271728A1/en not_active Application Discontinuation
- 2000-12-21 AR ARP000106853A patent/AR027066A1/en unknown
- 2000-12-21 GT GT200000220A patent/GT200000220A/en unknown
- 2000-12-22 PA PA20008508901A patent/PA8508901A1/en unknown
- 2000-12-22 TN TNTNSN00251A patent/TNSN00251A1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997037640A2 (en) * | 1996-04-05 | 1997-10-16 | Alza Corporation | Uniform drug delivery therapy |
WO1999001121A1 (en) * | 1997-07-01 | 1999-01-14 | Pfizer Inc. | Sertraline salts and sustained-release dosage forms of sertraline |
EP1027888A2 (en) * | 1999-02-10 | 2000-08-16 | Pfizer Products Inc. | Osmotic system for delivery of solid amorphous dispersions of drugs |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9060941B2 (en) | 2002-09-20 | 2015-06-23 | Actavis, Inc. | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
Also Published As
Publication number | Publication date |
---|---|
AU1724301A (en) | 2001-07-09 |
CA2395231C (en) | 2006-08-15 |
JP2003518487A (en) | 2003-06-10 |
AR027066A1 (en) | 2003-03-12 |
WO2001047498A2 (en) | 2001-07-05 |
US6899896B2 (en) | 2005-05-31 |
MXPA02006335A (en) | 2002-12-13 |
PE20010983A1 (en) | 2001-10-01 |
UY26493A1 (en) | 2001-07-31 |
BR0016707A (en) | 2002-09-03 |
GT200000220A (en) | 2002-06-14 |
CO5271728A1 (en) | 2003-04-30 |
PA8508901A1 (en) | 2003-12-10 |
TNSN00251A1 (en) | 2002-05-30 |
EP1239839A2 (en) | 2002-09-18 |
US20010044474A1 (en) | 2001-11-22 |
CA2395231A1 (en) | 2001-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001047498A3 (en) | Hydrogel-driven layered drug dosage form comprising sertraline | |
AP2002002553A0 (en) | Hydrogel-driven Drug Dosoge Form. | |
CA2191178A1 (en) | Long-lasting release nifedipine preparation | |
MY127797A (en) | 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol-containing pharmaceutical composition with slow release of active indgredient | |
AU5680100A (en) | Controlled release and taste masking oral pharmaceutical compositions | |
CA2232450A1 (en) | Oral pharmaceutical composition containing antimicrobial actives and sustained release pantoprazole | |
BG102228A (en) | Medicamentous form with controlled release of slightly soluble medicamentous substances | |
AU6517596A (en) | Oral pharmaceutical compositions with delayed release of reversible proton pump inhibitors | |
WO2003103637A3 (en) | Modified release, multiple unit drug delivery systems | |
CA2199778A1 (en) | Extended release formulation of venlafaxine | |
CA2346001A1 (en) | Controlled release nanoparticulate compositions | |
WO2001052823A3 (en) | Compositions to effect the release profile in the transdermal administration of drugs | |
WO2007052125A3 (en) | Solid oral pharmaceutical compositions for once daily dosing containing pregabalin, a matrix forming agent and a swelling agent | |
GEP20022851B (en) | Flash-Melt Oral Dosage Formulation | |
NZ524767A (en) | Composition for the transdermal delivery of fentanyl | |
CA2622805A1 (en) | Compressed tablets comprising valsartan | |
CA2312936A1 (en) | Compositions and methods for weight reduction | |
WO2005016306A3 (en) | Uniform delivery of topiramate over prolonged period of time with enhanced dispersion formulation | |
MXPA02006603A (en) | Brittle-coating, soft core dosage form. | |
HK1067299A1 (en) | Pharmaceutical compositions containing terbinafineand use thereof | |
CA2256751A1 (en) | Coated trimebutine maleate tablet | |
CA2340898A1 (en) | Compositions and methods for treating intracellular infections | |
AU2697100A (en) | Pharmaceutical capsule compositions containing loratadine and pseudoephedrine | |
WO2005020957A3 (en) | Stepwise delivery of topiramate over prolonged period of time | |
EP1782798A3 (en) | Ascending-dose dosage form |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000979866 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2395231 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/006335 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 548093 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 2000979866 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000979866 Country of ref document: EP |